Introducing .
作者信息
Elliott Tim
机构信息
Center for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton, UK.
出版信息
Immunother Adv. 2020 Nov 25;1(1):ltaa009. doi: 10.1093/immadv/ltaa009. eCollection 2021 Jan.
Abstract
摘要
相似文献
1
Introducing .
Immunother Adv. 2020 Nov 25;1(1):ltaa009. doi: 10.1093/immadv/ltaa009. eCollection 2021 Jan.
2
Self-Adjuvanting Polyguanidine Nanovaccines for Cancer Immunotherapy.
ACS Nano. 2024 Mar 5;18(9):7136-7147. doi: 10.1021/acsnano.3c11637. Epub 2024 Feb 26.
3
Updates and Recent Advances on Venom Immunotherapy.
Curr Treat Options Allergy. 2023 Apr 29:1-19. doi: 10.1007/s40521-023-00336-7.
4
Nanomedicines modulating tumor immunosuppressive cells to enhance cancer immunotherapy.
Acta Pharm Sin B. 2020 Nov;10(11):2054-2074. doi: 10.1016/j.apsb.2020.08.010. Epub 2020 Aug 27.
5
Bioengineered nanogels for cancer immunotherapy.
Chem Soc Rev. 2022 Jun 20;51(12):5136-5174. doi: 10.1039/d2cs00247g.
6
The evolution of biliary tract cancer: introducing a special focus issue from .
Immunotherapy. 2023 May;15(7):471-472. doi: 10.2217/imt-2023-0074. Epub 2023 Apr 5.
7
Introducing Volume 12 of .
Immunotherapy. 2020 Jan;12(1):1-3. doi: 10.2217/imt-2019-0225. Epub 2020 Jan 9.
8
Immunotherapy in hematological malignancies: recent advances and open questions.
Immunotherapy. 2021 Oct;13(14):1215-1229. doi: 10.2217/imt-2021-0065. Epub 2021 Sep 9.
9
Introducing Neoadjuvant Immunotherapy for Colorectal Cancer: Advancing the Frontier.
Ann Surg. 2025 Jan 1;281(1):95-104. doi: 10.1097/SLA.0000000000006443. Epub 2024 Jul 15.
10
Immunotherapy Advances: 2019.
Oncology (Williston Park). 2019 Oct 28;33(10):686508.
引用本文的文献
1
Visualizing Immune Checkpoint Inhibitors Derived Inflammation in Atherosclerosis.
Circ Res. 2024 Oct 25;135(10):990-1003. doi: 10.1161/CIRCRESAHA.124.324260. Epub 2024 Sep 27.
本文引用的文献
1
Recent advances in immunotherapies against infectious diseases.
Immunother Adv. 2020 Nov 25;1(1):ltaa007. doi: 10.1093/immadv/ltaa007. eCollection 2021 Jan.
2
Special Review: The future of Immunotherapy.
Immunother Adv. 2020 Nov 25;1(1):ltaa005. doi: 10.1093/immadv/ltaa005. eCollection 2021 Jan.
3
Vitamin D replacement enhances antigen-specific immunity in older adults.
Immunother Adv. 2020 Nov 25;1(1):ltaa008. doi: 10.1093/immadv/ltaa008. eCollection 2021 Jan.
4
DNAM1 and TIGIT balance the T cell response, with low T cell TIGIT expression corresponding to inflammation in psoriatic disease.
Immunother Adv. 2020 Nov 25;1(1):ltaa004. doi: 10.1093/immadv/ltaa004. eCollection 2021 Jan.
5
The MARVEL trial: a phase 2b randomised placebo-controlled trial of oral MitoQ in moderate ulcerative colitis.
Immunother Adv. 2020 Nov 12;1(1):ltaa002. doi: 10.1093/immadv/ltaa002. eCollection 2021 Jan.
6
Beyond Ipilimumab: a review of immunotherapeutic approaches in clinical trials in melanoma.
Immunother Adv. 2020 Dec 18;1(1):ltaa010. doi: 10.1093/immadv/ltaa010. eCollection 2021 Jan.
7
CAR-T cells leave the comfort zone: current and future applications beyond cancer.
Immunother Adv. 2020 Nov 25;1(1):ltaa006. doi: 10.1093/immadv/ltaa006. eCollection 2021 Jan.
8
Predicting clinical response to costimulation blockade in autoimmunity.
Immunother Adv. 2020 Nov 25;1(1):ltaa003. doi: 10.1093/immadv/ltaa003. eCollection 2021 Jan.
9
Protective low-avidity anti-tumour CD8+ T cells are selectively attenuated by regulatory T cells.
Immunother Adv. 2020 Nov 25;1(1):ltaa001. doi: 10.1093/immadv/ltaa001. eCollection 2021 Jan.
10
Clinical development of cell therapies for cancer: The regulators' perspective.
Eur J Cancer. 2020 Oct;138:41-53. doi: 10.1016/j.ejca.2020.07.006. Epub 2020 Aug 21.
Zotero 插件